Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users

Psychopharmacology

Volumn 167, Issue 1, 2003, Pages 85-96

  Thomasius, R ^a   Petersen, K ^a   Buchert, R ^a   Andresen, B ^a   Zapletalova, P ^a   Wartberg, L ^a   Nebeling, B ^a   Schmoldt, A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

3 4 Methylenedioxymethamphetamine; Cognitive performance; Ecstasy; MDMA; Neuroimaging; Psychopathology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; CAUDATE NUCLEUS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ABUSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PERFORMANCE; MESENCEPHALON; MOOD; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECALL; REGRESSION ANALYSIS; SEROTONINERGIC SYSTEM;

EID: 0038070346     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1383-9     Document Type: Article

References (77)

1. Acton PD, Friston KJ (1998) Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med 25:663-667
2. Bäumler G (1974) Lern- und Gedächtnistest LGT-3. Hogrefe, Göttingen
3. Bhattachary S, Powell JH (2001) Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or "ecstasy": evidence for cognitive impairment. Psychol Med 31:647-658
4. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51:1532-1537
5. Buchert R, Obrocki J, Thomasius R, Väterlein O, Petersen K, Jenicke L, Bohuslavizki, Clausen M (2001) Long term effects of "ecstasy"-abuse on the human brain studied by FDG PET. Nucl Med Commun 22:889-897
6. 11C](+)McN-5652: assessment of methods. J Cereb Blood Flow Metab 20: 253-262
7. Cole J, Sumnall H, Grob C (2002) Sorted: ecstasy, facts and fiction. Psychologist 15:464-467
8. Croft RJ, Mackay AJ, Mills AT, Gruzelier JG (2001) The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology: 153:373-379
9. Derogatis LR (1994) The SCL-90-R scoring manual. Distributed by National computer Systems, Minneapolis
10. Deykin EY, Levy JC, Wells V (1986) Adolescent depression, alcohol and drug abuse. Am J Public Health 76:178-182
11. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2002) Annual report on the state of the drugs problem in the European Union. Office for Official Publications of the European Communities, Luxembourg
12. Fox HC, Toplis AS, Turner JJD, Parrott AC (2001) Auditory verbal learning in drug-free ecstasy polydrug users. Hum Psychopharmacol Clin Exp 16:613-618
13. Franke G (1995) Die Symptom-Checkliste von Derogatis (SCL-90-R). Beltz, Göttingen
14. Gamma A, Frei E, Lehmann D, Pascual RD, Hell D, Vollenweider FX (2000) Mood state and brain electric activity in ecstasy users. Neuroreport 11:157-162
15. Gamma A, Frei E, Lehmann D, Pascual RD, Hell D, Vollenweider FX (2001) Mood state and brain electric activity in ecstasy users. Neuroreport 11:157-162
16. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R et al. (1998) Serotonergic function after 3,4-methylenedioxymethamphetamine ("ecstasy") in humans. Int Clin Psychopharmacol 13:1-9
17. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M et al. (2000) Long-lasting effects of 3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 47:127-136
18. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H-K, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68:719-725
19. Gsellhofer B, Fahrner EM, Platt J (1994) European Addiction Severity Index (EuropASI). Institute for Therapy Research (IFT), Munich, Germany
20. Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (±) 3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19:5096-5107
21. Heaton RK, Cheleene GJ, Talley JL, Kay GG, Curtiss G (1993) The Wisconsin Card Sorting Test (WCST) Manual - revised and expanded. Psychological Assessment Resources, Odessa, Fla.
22. 2 receptors with iodine-123-IBF SPECT. J Nucl Med 37:513-520
23. Ichise M, Meyer JH, Yonekura Y (2001) An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 42:755-763
24. Jäger AO, Althoff K (1994) Der Wilde-Intelligenz-Test (WIT) - ein Strukturdiagnostikum. Hogrefe, Göttingen
25. Khantzian EJ (1997) The self-medication hypothesis of substance abuse disorders: a reconsideration and recent applications. Harv Rev Psychiatry 4:231-244
26. Kish SJ (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71:845-855
27. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000) Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology 55:294-296
28. Klugman A, Hardy S, Baldeweg T, Gruzelier J (1999) Toxic effect of MDMA on brain serotonin neurons. Lancet 353:1269-1271
29. 3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry 24:299-309
30. Lehrl S (1995) Mehrfach-Wortschatz-Intelligenztest (MWT-B), 3. überarb. Aufl. Med. Verlagsgesellschaft, Balingen
31. Lezak MD (1983) Neuropsychological assessment, 2nd edn. Oxford University Press, New York
32. McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994) Serotonin neurotoxicity after (±) 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") users: a controlled study in humans. Neuropsychopharmacology 10:129-138
33. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437
34. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") users: a controlled study. Psychopharmacology 143:417-425
35. McGuire PK, Cope H, Fahy TA et al. (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ("ecstasy"). Br J Psychiatry 165:391-395
36. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M (1992) The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 9:199-213
37. Morgan MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology 141:30-36
38. Morgan MJ (2002) Throwing the baby out with the bath water? Psychologist 15:468-469
39. Morgan MJ, McFie L, Fleetwood LH, Robinson JA (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159:294-303
40. Obrocki J, Buchert R, Vätefiein O, Thomasius R, Beyer W, Schiemann T (1999) Ecstasy - long term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175:186-188
41. Parrott AC (2001)Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol Clin Exp 16:557-577
42. Parrott AC (2002) Very real, very damaging. Psychologist 15:472-473
43. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998) Cognitive performance in recreational users of MDMA or "ecstasy": evidence for memory deficits. J Psychopharmacol 12:79-83
44. Parrott AC, Sisk E, Turner JJD (2000) Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users. Drug Alcohol Depend 60:105-110
45. Parrott AC, Milani RM, Parmar R, Turner JD (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159:77-82
46. 11C]McN5652. J Nucl Med 41:1465-1477
47. Reitan RM (1992) Trail Making Test - manual for administration and scoring. Reitan Neuropsychology Laboratory, Tucson, Arizona
48. Reneman L, Booij J, Schmand B, Brink W, Gunning B (2000) Memory disturbances in "ecstasy" users are correlated with an altered serotonin neurotransmission. Psychopharmacology 148:322-324
49. Reneman L, Lavalaye J, Schmand B, De Wolff FA, van den Brink W, den Heeten GJ, Booij J (2001a) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). Arch Gen Psychiatry 58:901-906
50. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GI, van den Brink W (2001b) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358:1864-1869
51. Reneman L, Majoie CBLM, Schmand B, van den Brink W, den Heeten GJ (2001c) Prefrontal N-acetylaspanate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol Psychiatry 50:550-554
52. Reneman L, Majoie CBLM, Flick H, den Heeten GJ (2002) Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (ecstasy) users: preliminary results. Am J Neuroradiol 23:231-237
53. Ricaune GA, Finnegan KT, Irwin I, Langston JW (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann NY Acad Sci 600:699-710
54. Ricaurte GA, Yuan J, McCann UD (2000) (±) 3,4-Methylenedioxymethamphetamine ("ecstasy")-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5-10
55. Rodgers J (2000) Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151:19-24
56. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA (1998) In vivo detection of short- and long-term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse 29:183-192
57. Schuster P, Lieb R, Lamertz C, Wittchen HU (1998) Is the use of ecstasy and hallucinogens increasing? Eur Addict Res 4:75-82
58. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry 175:63-69
59. Simon et al. (2001)
60. Strote J, Lee JE, Wechsler H (2002) Increasing MDMA use among college students: result of a national survey. J Adolesc Health 72:64-72
61. 11C]McN-5652-Z. J Label Comp Radiopharm 31:841-848
62. 11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci 53:883-892
63. 11C](+)McN5652. Synapse 20:3743
64. Szabo Z, Kao PF, Mathews WB, Raven HT, Musachio JL, Scheffel U, Dannals RF (1996) Positron emission tomography of 5-HT reuptake sites in the human brain with C-11 McN5652 extraction of characteristic images by artificial neural network analysis. Behav Brain Res 73:221-222
65. 11-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43:678-692
66. Tewes U (1994) HAWIE-R: Hamburg Wechsler Intelligenztest für Erwachsene, Revision 1991. Huber, Bern
67. Thomasius R (ed) (2000) Ecstasy. Eine Studie zu gesundheitlichen und psychosozialen Folgen des Missbrauchs. Wissenschaftliche Verlagsgesellschaft, Stuttgart
68. Tossmann P, Boldt S, Tensil MD (2001) The use of drugs within the Techno Party Scene in European Metropolitan Cities. Eur Addict Res 7:2-23
69. Tuchtenhagen F, Daumann J, Norra C, Gobbele R, Becker S, Pelz S, Sass H, Buchner H, Gouzoulis-Mayfrank E (2000) High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 22:608-617
70. Verkes RJ, Gijsman HJ, Pieters MS, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJ, de Bruin D, Van de Wijngaart G, Van Gerven JM, Cohen AF (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153:196-202
71. Wareing M, Fisk JE, Murphy PN (2000) Working memory deficits in current and previous users of MDMA ("ecstasy"). Br J Psychol 91:181-188
72. 11C-Diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab 17:943-949
73. Wienhard K, Eriksson L, Grootoonk S, Casey M (1992) Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr 16:804-813
74. Wilson B, Cockburn J, Baddeley A (1985) The Rivermead Behavioural Memory Test. Thames Valley Text, Reading
75. Wittchen HU, Zaudig M, Fytrich T (1997) Strukturiertes klinisches Interview für DSM-IV (SKID I and II, Structured clinical interview for the DSM-IV). Hogrefe, Göttingen
76. Zakzanis KK, Young DA (2001) Executive function in abstinent MDMA ("ecstasy") users. Med Sci Monit 7:1292-1298
77. Zimmermann P, Flimm B (1993) Testbatterie zur Aufmerksam-keitsprüfung (TAP) Version 1.02. Vera Fimm/Psychologische Testsysteme, Wuerselen